SCHEMBL23973158

SCHEMBL23973158

O=c1[nH]c(C2(c3cccc(C(F)(F)F)c3)CC2)nc2c1CNCCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
WNT3A P56704 5/20 0.41
TNKS2 Q9H2K2 5/20 0.41
TNKS O95271 4/20 0.41
PARP1 P09874 4/20 0.41
TP53 P04637 1/20 0.35
SLC6A4 P31645 3/20 0.34
PARP2 Q9UGN5 2/20 0.34
PARP14 Q460N5 1/20 0.34
PARP4 Q9UKK3 1/20 0.34
AXIN2 Q9Y2T1 1/20 0.34
PARP3 Q9Y6F1 1/20 0.34
TACR1 P25103 1/20 0.33
HTR6 P50406 1/20 0.33
ASIC3 Q9UHC3 1/20 0.33
RAF1 P04049 1/20 0.33
BRAF P15056 1/20 0.33
HPGD P15428 1/20 0.33
SLC6A3 Q01959 2/20 0.33
SLC6A2 P23975 1/20 0.33
MCHR1 Q99705 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23973163 0.87 HPGD (0.43) WNT3ATNKS2TNKSPARP1HPGD
SCHEMBL23973335 0.86 TNKS2 (0.38) WNT3ATNKS2TNKSPARP1SLC6A4
SCHEMBL23973268 0.86 TNKS2 (0.39) WNT3ATNKS2TNKSPARP1TP53
SCHEMBL23973164 0.85 LMNA (0.41) TNKS2TNKSHPGD
SCHEMBL23973166 0.85 SPR (0.41) WNT3ATNKS2TNKSPARP1HPGD
SCHEMBL23972365 0.84 HPGD (0.38) TNKS2TNKSPARP1HPGDOPRM1
SCHEMBL23973165 0.82 TNKS2 (0.44) WNT3ATNKS2TNKSPARP1HPGD
SCHEMBL23973345 0.82 TNKS (0.37) TNKS2TNKSTP53PARP2HPGD
SCHEMBL23973264 0.81 SMN1; SMN2 (0.38) TNKS2TNKSPARP1HPGD
SCHEMBL23973232 0.81 TNKS2 (0.46) WNT3ATNKS2TNKSPARP1PARP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4142874-B1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2026-04-22 EP disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2023-10-26 US disclosed
WO-2021221169-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339934-A1 PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS TRPV4, TRPV1, TRPV2 WNT3A 2816/4885TNKS2 1601/4885TNKS 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.